

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :C07D 405/12, 405/14, 311/58
C07D 405/06, A61K 31/35

A1

(11) International Publication Number:

WO 93/17017

(43) International Publication Date:

2 September 1993 (02.09.93)

(21) International Application Number: PCT/EP93/00435

(22) International Filing Date: 19 February 1993 (19.02.93)

(30) Priority data:

842,560

27 February 1992 (27.02.92) US

(60) Parent Application or Grant

(63) Related by Continuation

US

Filed on

842,560 (CIP)

27 February 1992 (27.02.92)


(71) Applicant (for all designated States except US): JANSSEN
PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30,
B-2340 Beerse (BE).

(72) Inventors; and


(75) Inventors/Applicants (for US only): VAN LOMMEN, Guy,
Rosalia, Eugène [BE/BE]; Klets 34, B-2590 Berlaar
(BE). DE BRUYN, Marcel, Frans, Leopold [BE/BE];
Pater Schrijversstraat 4, B-2323 Hoogstraten (BE).
JANSSENS, Walter, Jacobus, Joseph [BE/BE]; St Lam-
bertusstraat 8, B-2340 Beerse (BE).(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica
N.V., Patent Department, Turnhoutseweg 30, B-2340 Be-
erse (BE).(81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP,
KP, KR, LK, MG, MN, MW, NO, NZ, PL, PT, RO,
RU, SD, SK, UA, US, European patent (AT, BE, CH,
DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, SN, TD, TG).

Published


With international search report.

(54) Title: [(BENZODIOXAN, BENZOFURAN OR BENZOPYRAN)-ALKYLAMINO] ALKYL SUBSTITUTED GUANI-
DINES AS SELECTIVE VASOCONSTRICTORS


(I)




(a)




(b)



(c)



(d)



(e)

(57) Abstract

The present invention is concerned with vasoconstrictive [(benzodioxan, benzofuran or benzopyran)alkylamino]alkyl substituted guanidines having formula (I), the pharmaceutically acceptable acid addition salts thereof, and the stereochemically isomeric forms thereof, wherein X is O, CH₂ or a direct bond; R¹ is hydrogen or C₁₋₆alkyl; R² is hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl or C₃₋₆alkynyl; R³ is hydrogen or C₁₋₆alkyl; or R² and R³ may be taken together to form a bivalent radical of formula -(CH₂)_m-, wherein m is 4 or 5; or R¹ and R² taken together may form a bivalent radical of formula -CH=CH- or of formula -(CH₂)_n-, wherein n is 2, 3 or 4; or R³ may represent a bond when R¹ and R² taken together form a bivalent radical of formula -CH=CH-CH=, -CH=CH-N=, or -CH=N-CH=; R⁴ is hydrogen or C₁₋₆alkyl; Alk¹ is a bivalent C₁₋₃alkanediyl radical; A is a bivalent radical of formula (a), (b), (c), (d), (e), wherein each R⁵ is hydrogen or C₁₋₄alkyl; Alk² is C₂₋₁₅alkanediyl or C₅₋₇cycloalkanediyl; and each p is 0, 1 or 2; provided that [2-[2,3-dihydro-1,4-benzodioxin-2-yl)methyl]aminoethyl guanidine is excluded. Pharmaceuticals which are useful as vasoconstrictors. Compositions comprising said guanidine derivatives as active ingredients, processes for preparing said guanidine derivatives and novel N-cyano guanidine, intermediates; and a use as a medicine are described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MD	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5


[(BENZODIOXAN, BENZOFURAN OR BENZOPYRAN)-ALKYLAMINO] ALKYL
SUBSTITUTED GUANIDINES AS SELECTIVE VASOCONSTRICTORS

Background of the invention

10 In EP-0,387,771 there are described benzopyran derivatives which show an inhibitory activity on Maillard reaction and possess an antioxidizing effect. In *Arzneim.-Forsch.* 25 (9), p. 1404 (1975) there is described [2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-amino]ethylguanidine in a study concerning noradrenaline depletion effects. In WO-83/03607 a number of cyanoguanidines are described having anti-hypertensive and
15 vasodilator activity. Our novel compounds differ in that they have selective vasoconstrictor activity.

Description of the invention

20 The present invention is concerned with [(benzodioxan, benzofuran or benzopyran)alkylamino]alkyl substituted guanidines having the formula



the pharmaceutically acceptable acid addition salts thereof, and the stereochemically isomeric
25 forms thereof, wherein






- X is O, CH₂ or a direct bond;
- R¹ is hydrogen or C₁₋₆alkyl;
- R² is hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl or C₃₋₆alkynyl;
- 30 R³ is hydrogen or C₁₋₆alkyl; or
- R² and R³ taken together form a bivalent radical of formula -(CH₂)_m- wherein m is 4 or 5; or
- R¹ and R² taken together form a bivalent radical of formula -CH=CH- or of formula -(CH₂)_n-, wherein n is 2, 3 or 4; or
- 35 R³ may represent a bond when R¹ and R² taken together form a bivalent radical of

formula $-\text{CH}=\text{CH}-\text{CH}=\text{}$, $-\text{CH}=\text{CH}-\text{N}=\text{}$, or $-\text{CH}=\text{N}-\text{CH}=\text{}$, wherein one or two hydrogen atoms can be replaced by halo, C_{1-6} alkyl, C_{1-6} alkyloxy, cyano, amino, mono- or di(C_{1-6} alkyl)amino, mono- or di(C_{3-6} cycloalkyl)amino, aminocarbonyl, C_{1-6} alkyloxycarbonylamino, C_{1-6} alkylaminocarbonylamino;

5 R^4 is hydrogen or C_{1-6} alkyl;

Alk^1 is a bivalent C_{1-3} alkanediyl radical;

A is a bivalent radical of formula :



wherein each R^5 is hydrogen or C_{1-4} alkyl;

wherein each R^6 is hydrogen or C_{1-4} alkyl;

15 Alk^2 is C_{2-15} alkanediyl or C_{5-7} cycloalkanediyl;

and each p is 0, 1 or 2; and

R^7 and R^8 each independently are hydrogen, halo, C_{1-6} alkyl, C_{3-6} alkenyl,

C_{3-6} alkynyl, hydroxy, C_{1-6} alkyloxy, cyano, amino C_{1-6} alkyl, carboxyl,

C_{1-6} alkyloxycarbonyl, nitro, amino, aminocarbonyl, C_{1-6} alkylcarbonylamino,

20 or mono- or di(C_{1-6} alkyl)amino;

provided that [2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]ethyl guanidine is excluded.

The compounds of formula (I) wherein R^2 , R^3 or R^6 are hydrogen may also exist in their
25 tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

As used in the foregoing definitions halo defines fluoro, chloro, bromo and iodo; C₁₋₄alkyl defines straight and branch chained saturated hydrocarbon radicals having 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl and the like; C₁₋₆alkyl defines C₁₋₄alkyl and the higher homologues thereof having 5 to 6 carbon atoms such as, for example, pentyl, hexyl, 1-methylbutyl and the like; C₃₋₆alkenyl defines straight and branch chained hydrocarbon radicals containing one double bond and having from 3 to 6 carbon atoms, such as, for example, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl and the like; and the carbon atom of said C₃₋₆alkenyl being connected to a nitrogen atom preferably is saturated, C₃₋₆alkynyl defines straight and branch chained hydrocarbon radicals containing one triple bond and having from 3 to 6 carbon atoms, such as, for example, 2-propynyl, 3-butyne, 2-butyne, 2-pentyne, 3-pentyne, 3-hexyne, and the like; and the carbon atom of said C₃₋₆alkynyl radical being connected to a nitrogen atom preferably is saturated; C₃₋₆cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; C₁₋₃alkanediyl defines bivalent straight and branch chained saturated hydrocarbon radicals having from 1 to 3 carbon atoms, such as, for example, methane-diyl, 1,2-ethanediyl, 1,3-propanediyl, 1,2-propanediyl and the like; C₂₋₁₅alkanediyl defines bivalent straight and branch chained saturated hydrocarbon radicals having from 2 to 15 carbon atoms such as, for example, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl, 1,7-heptanediyl, 1,8-octanediyl, 1,9-nonanediyl, 1,10-decanediyl, 1,11-undecanediyl, 1,12-dodecanediyl, 1,13-tridecanediyl, 1,14-tetradecanediyl, 1,15-pentadecanediyl, and the branched isomers thereof; C₅₋₇cycloalkanediyl defines bivalent cyclic saturated hydrocarbon radicals such as, for example, 1,2-cyclopentanediy, 1,3-cyclopentanediy, 1,2-cyclohexanediy, 1,3-cyclohexanediy, 1,4-cyclohexanediy, 1,2-cycloheptanediy, 1,3-cycloheptanediy, 1,4-cycloheptanediy.

The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free


base form.

The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

5

The $\begin{array}{c} \text{N}-\text{R}^1 \\ || \\ -\text{C}-\text{NR}^2\text{R}^3 \end{array}$ moiety may be acyclic in which case R^1 preferably is hydrogen, methyl or ethyl; R^2 preferably is hydrogen, methyl, ethyl, propyl or butyl; R^3 preferably is hydrogen, methyl or ethyl. Said moiety may also be cyclic in which case it can represent radicals of formula :

10



15

wherein R^3 in particular is hydrogen or methyl. The latter cyclic moieties may be unsubstituted or substituted, preferably with halo, especially iodo; C_{1-6} alkyl, especially methyl; C_{1-6} alkyloxy, especially methoxy; cyano; amino; di C_{1-6} alkylamino, especially, dimethylamino; or aminocarbonyl.

20

Interesting compounds are those compounds of formula (I), wherein Alk^1 is $-\text{CH}_2-\text{CH}_2-$ or $-\text{CH}_2-$, especially $-\text{CH}_2-$.

Also interesting are those compounds of formula (I) wherein R^4 is hydrogen or C_{1-4} alkyl, especially methyl.

25

Further interesting compounds are those compounds of formula (I) wherein X is CH_2 and wherein R^7 and R^8 each independently are hydrogen; halo, preferably fluoro, chloro or bromo; C_{1-6} alkyl, preferably methyl, ethyl, propyl or butyl; C_{1-6} alkyloxy, preferably methoxy; hydroxy; cyano; amino; amino C_{1-6} alkyl, preferably aminomethyl; C_{1-6} alkylcarbonylamino, preferably methylcarbonylamino; or nitro.

30


Other interesting compounds are those compounds of formula (I) wherein X is O and wherein R^7 and R^8 each independently are hydrogen; halo, preferably fluoro, chloro, bromo; C_{1-6} alkyl, preferably methyl or ethyl; C_{1-6} alkyloxy, preferably methoxy; hydroxy, cyano or nitro.

Still other interesting compounds are those compounds wherein X is a direct bond and wherein R⁷ and R⁸ each independently are hydrogen, halo, preferably fluoro, chloro or bromo; or C₁₋₆alkyl, preferably methyl or ethyl.

Particular compounds are those compounds of formula (I) wherein A represents a radical of formula (a); Alk² is C₂₋₁₅alkanediyl, especially C₂₋₁₀alkanediyl, more in particular C₂₋₆alkanediyl, preferably 1,3-propanediyl; R⁵ is hydrogen or methyl; and R⁶ is hydrogen or methyl.

Further particular compounds are those compounds of formula (I), wherein A represents a radical of formula (b) or (c), p is 0, 1 or 2, especially 0 or 1, preferably 1; and wherein R⁵ and R⁶ each independently are hydrogen or methyl.

Particularly interesting are those compounds wherein the absolute configuration of the the carbonatom at the 2-position in formula (I), indicated with an asterisk (*), is as shown in the formula hereunder.



Particularly interesting compounds are those interesting or particular compounds having substituents on the 7- or 8- position (as defined in formula (I)) of the benzodioxan, benzofuran or benzopyran moiety.

Preferred compounds are those compounds of formula (I), wherein X is CH₂, R⁷ and R⁸ each independently are hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy or cyano, especially when substituted on the 7- or 8-position of the benzopyran moiety, and wherein A represents a radical of formula (a), wherein Alk² represents C₂₋₁₀alkanediyl and R⁵ and R⁶ each independently are hydrogen.

Most preferred compounds are N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(1,4,5,6-tetrahydro-2-pyrimidinyl)-1,3-propanediamine, the stereochemical isomers thereof, particularly the R-isomer, and the pharmaceutically acceptable acid addition salts thereof.

The term "stereochemically isomeric forms" as used hereinbefore defines all the


possible isomeric forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular,

5 stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic saturated hydrocarbon radicals may have either the cis- or trans-configuration and C₃₋₆-alkenyl radicals may have the E- or Z-configuration. Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention.

10

The compounds of formula (I) can generally be prepared by reacting a diamine of formula (II) wherein A, R⁴, R⁷ and R⁸ are as defined under formula (I) with a reagent of formula (III) wherein R¹, R² and R³ are defined under formula (I) and W₁ is a reactive leaving group such as, for example, halo, e.g. chloro, bromo; alkyloxy, e.g. methoxy, ethoxy and the like; aryloxy, e.g. phenoxy and the like; alkylthio, e.g. methylthio, ethylthio and the like; arylthio, e.g. benzenethio and the like.

15





20 Said reaction can be performed by stirring the diamine of formula (II) with the reagent of formula (III) in an appropriate solvent such as, for example, an alcohol, e.g. methanol, ethanol, propanol and the like; a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane and the like or an ether, e.g. 1,1'-oxybisethane, 2,2'-oxybispropane, tetrahydrofuran, 1,4-dioxane and the like; an aromatic hydrocarbon, e.g. benzene,

25 methylbenzene, dimethylbenzene and the like. Optionally a base, such as, for example, an alkalimetal carbonate, e.g. sodium or potassium carbonate; an alkalimetal hydrogen carbonate, e.g. sodium or potassium hydrogen carbonate; an appropriate organic base, e.g. N,N-diethylethanamine, pyridine, N-(1-methylethyl)-2-propanamine and the like bases, can be added to pick up the acid that may be formed during the course of the

30 reaction. Elevated temperatures may enhance the rate of the reaction. Preferably the reaction is performed at the reflux temperature of the reaction mixture.

The compounds of formula (I) can also generally be prepared by reductive N-alkylation of an aminoderivative of formula (VI) with an appropriate aldehyde of

formula (V), wherein r is 0, 1 or 2.




- 5 Said reaction is performed by stirring the reactants in an appropriate solvent such as, for example, an alcohol, e.g. methanol, ethanol, propanol and the like; an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like; an aromatic solvent, e.g. benzene, methylbenzene, dimethylbenzene and the like. Optionally a water separator can be used to remove the water that is formed during the course of the reaction. The
- 10 resulting imine can then be reduced by catalytic hydrogenation on an appropriate catalyst, such as, for example palladium on charcoal, palladium on bariumsulfate, platinum on charcoal, Raney-Nickel and the like in a suitable solvent, such as, for example an alcohol, e.g. methanol, ethanol and the like; an ether, e.g. tetrahydrofuran, 1,4-dioxane and the like; a carboxylic ester, e.g. ethyl acetate, butyl acetate and the like; or a carboxylic acid,
- 15 e.g. acetic acid, propanoic acid and the like. Optionally the reaction may be performed at elevated temperatures and/or pressures.

- The intermediate aldehyde of formula (V) can be formed by reducing an acyl derivative of formula (IV) wherein r is defined as above and Y is halo, e.g. chloro, bromo. The acyl halide can be formed by reacting the acid of formula (IV) wherein
- 20 $Y = OH$, with a halogenating reagent such as thionylchloride, phosphorus trichloride, phosphorus tribromide, oxalylchloride and the like. The latter reaction may be performed in an excess of the halogenating reagent or in appropriate solvents such as for example halogenated hydrocarbons, e.g. dichloromethane, trichloromethane and the like; aromatic hydrocarbons, e.g. benzene, methylbenzene, dimethylbenzene and the like; ethers, e.g.
- 25 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like, or dipolar aprotic solvents, e.g. *N,N*-dimethylformamide, *N,N*-dimethylacetamide and the like. Stirring and elevated temperatures may be appropriate to enhance the rate of the reaction. Said reduction of the acylhalide of formula (IV) can for instance be performed by

catalytic hydrogenation with a catalyst such as palladium on charcoal, palladium on bariumsulfate, platinum on charcoal and the like in appropriate solvents such as, for example ethers, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like; preferably in admixture of a dipolar aprotic solvent, such as, for example N,N-dimethylformamide, N,N-dimethylacetamide and the like. Optionally a catalyst poison can be added, such as thiophene, quinoline-sulfur and the like.


The reaction sequence starting from the intermediate aldehyde of formula (IV) and yielding compounds of formula (I) may be performed as a one-pot reaction.

10 The compounds of formula (I) can also be prepared by N-alkylating an amine of formula (VI) with an intermediate of formula (VII), wherein W_2 is a reactive leaving group such as, for example, halo, e.g. chloro, bromo or iodo; sulfonyloxy, e.g. methanesulfonyloxy, benzenesulfonyloxy, methylbenzenesulfonyloxy and the like, in appropriate solvents such as ketones, e.g. 2-propanone, 2-butanone and the like; ethers, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like; aromatic hydrocarbons, e.g. benzene, methylbenzene and the like; dipolar aprotic solvents, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide and the like.




20 Stirring and heating may enhance the reaction rate. Optionally a suitable base may be added to pick up the acid that is formed during the course of the reaction, such as, for example an alkali metal carbonate, e.g. sodium carbonate, potassium carbonate; an alkali metal hydrogen carbonate, e.g. sodium hydrogen carbonate, potassium hydrogen carbonate and the like; an appropriate organic base, e.g. N,N-diethylethanamine, pyridine and the like.

The compounds of formula (I), wherein A is a bivalent radical of formula (a) and R⁵ is hydrogen, said compounds being represented by formula (I-a), may be prepared by debenzylation of an intermediate of formula (VIII).



- Said debenzylation can be performed following art-known procedures such as catalytic hydrogenation using appropriate catalysts, e.g. platinum on charcoal, palladium on charcoal, in appropriate solvents such as alcohols, e.g. methanol, ethanol, 2-propanol and the like; ethers e.g. 1,1'-oxybisethane, tetrahydrofuran, 2,2'-oxybispropane and the like. Optionally elevated temperatures and pressures may be applied.

- The compounds of formula (I) wherein R^1 is hydrogen, said compounds being represented by formula (I-b), can be prepared by hydrolysis of the intermediate cyanoguanidines represented by formula (IX-a).



- Said hydrolysis can be performed by stirring the intermediate cyanoguanidine of formula (IX-a) in the presence of an acid such as, for example a mineral acid, e.g. hydrochloric acid, hydrobromic acid, sulfuric acid and the like or an organic acid, e.g. acetic acid, formic acid and the like, optionally in admixture with an appropriate solvent such as, for example, an alcohol, e.g. methanol, ethanol, propanol and the like; an ether, e.g. 1,1'-oxybisethane, 2,2'-oxybispropane, tetrahydrofuran, 1,4-dioxane and the like. In the course of this hydrolysis the intermediate (IX-b) can be formed. Said intermediate of formula (IX-b) can sometimes be isolated, and further hydrolyzed yielding compounds of formula (I).

The compounds of formula (I), can also be converted into each other by functional group transformations.

For instance the compounds of formula (I), wherein the $\text{—}\overset{\text{N-R}^1}{\underset{||}{\text{C}}}\text{—NR}^2\text{R}^3$ moiety represents a pyrimidinyl moiety, said compounds being represented by formula (I-c), can be converted into the tetrahydroanalogs (I-d) following art-known catalytic hydrogenation procedures.




This reduction can be performed simultaneously with the debenzylation mentioned hereinabove in describing the synthesis of the compounds of formula (I-a).

Furthermore, compounds of formula (I) bearing a C₃₋₆alkynylgroup or C₃₋₆alkenylgroup can be converted into the corresponding compounds bearing C₁₋₆alkylgroup following art-known hydrogenation techniques. Compounds of formula (I) bearing a cyanogroup can be converted into the corresponding compounds bearing an aminomethyl substituent following art-known hydrogenation techniques. Compounds bearing an alkyloxy substituent can be converted into compounds bearing a hydroxygroup by treating the alkyloxy compound with an appropriate acidic reagent such as for example, hydrohalic acid, e.g. hydrobromic acid or borontribromide and the like. Compounds bearing an amino substituent can be N-acylated or N-alkylated following art-known N-acylation or N-alkylation procedures.

A number of intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies of preparing said or similar compounds and some intermediates are new. A number of preparation methods will be described hereinafter in more detail.

The intermediates of formula (II) wherein A is a radical of formula (a) and R⁶ is hydrogen, said intermediates being represented by formula (II-a), can be prepared by reducing a nitrile of the formula (X) wherein q is 1 to 14, using art-known reduction conditions. Said reduction can, for instance, be performed by catalytic hydrogenation using an appropriate catalyst, such as, for example, Raney nickel, palladium on charcoal, palladium on bariumsulfate and the like, in an appropriate solvent, such as, for example, an alcohol, e.g. methanol, ethanol, propanol and the like; an ether, e.g. 2,2'-oxybispropane, tetrahydrofuran, 1,4-dioxane and the like, or a mixture of such solvents.

Preferably the reduction is conducted in the presence of ammonia. Optionally higher temperatures or pressures can be applied.




5

Said reduction can also be carried out by stirring the nitrile with a reducing reagent, such as, for example, borane, lithium aluminum hydride, and the like, in an appropriate solvent, such as an ether, e.g. 2,2'-oxybispropane, tetrahydrofuran, 1,4-dioxane and the like; or a hydrocarbon, e.g. pentane, hexane and the like; an aromatic solvent, e.g. benzene, methylbenzene, dimethylbenzene and the like. Optionally elevated temperatures can be applied to enhance the reaction rate.

10

The intermediates of formula (X) can be prepared by reacting an amine of formula (XI) with a reagent of formula (XII), wherein W_2 and q are defined as hereinabove, in an appropriate solvent such as, for example, a dipolar aprotic solvent, e.g. *N,N*-dimethylformamide, dimethylsulfoxide, acetonitrile and the like, an aromatic solvent, e.g. benzene, methylbenzene, dimethylbenzene and the like; a ketone, e.g. 2-propanone, 4-methyl-2-pentanone and the like; an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like.

15




20

A base as mentioned in the preparation of compounds of formula (I) from intermediates of formula (II) and (III) may be added to pick up the acid that is formed during the course of the reaction. Stirring and elevated temperatures may enhance the reaction rate. In the formula of the intermediate amine (XI) R^5 may also have the meaning of benzyl. This protective group can then be removed in a later stage of the synthesis.

25

For the preparation of intermediates of formula (X) wherein $q = 2$, said intermediates being represented by formula (X-a) an interesting alternative for the above alkylation comprises stirring the amine of formula (XI) with 2-propenenitrile in an appropriate solvent such as for example, an alcohol, e.g. methanol, ethanol, propanol and the like, an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like.


30



Elevated temperatures may be appropriate to enhance the rate of the reaction. Preferably the reactants are stirred at the reflux temperature of the reaction mixture.


The intermediates of formula (IX-a), wherein R^4 , R^7 , R^8 , X , Alk^1 are as defined hereinabove and A is a bivalent radical of formula (a), (c), (d), (e); and wherein R^2 is hydrogen, C_1 -alkyl, C_3 -alkenyl, or C_3 -alkynyl, and R^3 is hydrogen or C_1 -alkyl, or R^2 and R^3 taken together form a bivalent radical of formula $-(\text{CH}_2)_m-$, wherein m is 4 or 5, are deemed novel.

The intermediates of formula (IX-a) can be prepared by reacting an intermediate of formula (II) with a reagent of formula (XIII), wherein W_1 is a reactive leaving group as defined under formula (III),



Said reaction can be performed by stirring the reactants in an appropriate solvent such as an alcohol, e.g. methanol, ethanol and the like, an halogenated hydrocarbon, e.g. dichloromethane, trichloromethane and the like, an aromatic solvent, e.g. benzene, methylbenzene, dimethylbenzene and the like, a dipolar aprotic solvent, e.g. *N,N*-dimethylformamide, *N,N*-dimethylacetamide and the like. Optionally a base as mentioned under the preparation of the compounds of formula (I) from intermediates of formula (II) and (III) can be added to pick up the acid that is formed during the course of the reaction. Preferably the reaction is performed at room temperature.

The intermediates of formula (XIII) can be prepared by reacting a cyanamide of formula (XIV) wherein W_1 is defined as under formula (III), with an amine of formula (XV).



Said reaction can be performed by stirring the reactants in a reaction-inert solvent such as, for example, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane and the like, an aromatic solvent, e.g. benzene, methylbenzene and the like, an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like. Optionally a base can be added to pick up the acid that is formed in the course of the reaction. Appropriate bases are alkali metal or earth alkaline metal carbonates or hydrogen carbonates, e.g. sodium carbonate, sodium hydrogen carbonate, potassium carbonate and the like. Elevated temperatures may enhance the reaction rate.

Pure stereochemically isomeric forms of the compounds of this invention may be obtained by the application of art-known procedures. Diastereoisomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. liquid chromatography. Enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials. Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be included within the scope of the invention.

The compounds of formula (I), the pharmaceutically acceptable acid-addition salts and stereochemically isomeric forms thereof have interesting pharmacological properties : they show 5HT₁-like agonistic activity. The compounds of the present invention have potent and selective vasoconstrictor activity. They are useful to treat conditions which are related to vasodilatation. For instance, they are useful in the treatment of conditions characterized by or associated with cephalic pain, e.g. migraine, cluster headache and headache associated with vascular disorders. These compounds are also useful in the treatment of venous insufficiency and in the treatment of conditions associated with hypotension.

The vasoconstrictor activity of the compounds of formula (I) can be determined using an

in vitro-test as is described in "Instantaneous changes of alpha-adrenoreceptor affinity caused by moderate cooling in canine cutaneous veins" in the American Journal of Physiology 234(4), H330-H337, 1978; or in the test described in the pharmacological example, wherein the serotonin-like response of the compounds of the present invention was tested on the basilar arteries of pigs. Novel intermediates of formula (IX-a) as defined hereinabove show similar pharmacological activity.

In view of their useful pharmacological properties, the subject compounds may be formulated into various pharmaceutical forms for administration purposes.

- 10 To prepare the pharmaceutical compositions of this invention, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form
- 15 suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants,
- 20 binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example,
- 25 may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing
- 30 agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. It is
- 35 especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as

unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or
5 suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

The compounds of the present invention therefore may be used as medicines in conditions related to vasodilatation, more in particular hypotension, venous insufficiency and especially cephalic pain among which migraine. The compounds of the present
10 invention also provide a method of treating warm-blooded animals suffering from conditions related to vasodilatation, such as, hypotension, venous insufficiency and especially cephalic pain among which migraine by administering an effective amount of a compound of formula (I), a pharmaceutically acceptable acid addition salt or a stereoisomeric form thereof. Those skilled in the art could easily determine the effective
15 amount from the test results presented hereinafter. In general it is contemplated that an effective amount would be from 1 µg/kg to 1 mg/kg body weight, and in particular from 2 µg/kg to 200 µg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.005 to 20
20 mg, and in particular 0.1 mg to 10 mg of active ingredient per unit dosage form.

The following examples are intended to illustrate and not to limit the scope of the present invention in all its aspects.

25 Experimental part

A. Preparation of the intermediates

Example 1

a) To a stirred and cooled (0°C) solution of 32.8 g of 3,4-dihydro-2H-1-benzopyran-2-methanol in 71 ml of pyridine and 135 ml of benzene was added dropwise a solution of
30 41.9 g of 4-methyl-benzenesulfonyl chloride in 72.5 ml of benzene. Upon completion, stirring was continued for 25 hours. The reaction mixture was washed successively with a hydrochloric acid solution (10%), with water and with a sodium carbonate solution (10%). The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CHCl₃ 100%). The eluent of the desired fraction
35 was evaporated, yielding 28.3 g of 3,4-dihydro-2H-1-benzopyran-2-methanol 4-methylbenzenesulfonate (ester) as a solid residue, mp. 59.4°C (interm. 1).

In a similar way there was also prepared :

6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol 4-methylbenzenesulfonate (ester) (interm. 2).

- b) A mixture of 7.7 g of intermediate (1), 5.3 g of benzenemethanamine, 5 g of sodium carbonate and 250 ml of 4-methyl-2-pentanone was stirred and refluxed for 48 hours using a water-separator. The reaction mixture was cooled and washed with water. The organic phase was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CHCl₃ / CH₃OH 90:10). The eluent of the desired fraction was evaporated and the residue was converted into the ethanedioate salt in ethanol. The salt was filtered off and suspended in 2-propanone. The product was filtered off and dried, yielding 1.16 g (19.5%) of 3,4-dihydro-N-(phenylmethyl)-2H-1-benzopyran-2-methanamine ethanedioate (1:1) (interm. 3).

In a similar way there was also prepared :

2,3-dihydro-N-(phenylmethyl)-1,4-benzodioxine-2-methanamine (interm. 4).

15 Example 2

In EP-0.145.067 the synthesis of (+)-6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid (interm. 5) is described.

- a) To a stirred and heated ($\pm 80^{\circ}\text{C}$) mixture of 49.05 g of intermediate (5) and 244 ml of methylbenzene were added dropwise 54 ml of thionyl chloride during a period of 85 minutes. Upon complete addition, stirring was continued for 2 hours at 80°C . After cooling to room temperature, the reaction mixture was evaporated. The residue was taken up in methylbenzene and the solvent was evaporated again, yielding 60.4 g (100%) of (+)-(S)-6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carbonyl chloride as a residue (interm. 6).
- b) A mixture of 46.9 g of intermediate (6) in 60 ml of N,N-dimethylacetamide and 350 ml of 2,2'-oxybispropane was hydrogenated in the presence of 3 g of palladium-on-charcoal catalyst (10%) and 5 ml of a solution of thiophene in methanol (4%). After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was added to a mixture of 25 g of benzenemethanamine, 20 g of potassium acetate and 300 ml of methanol. This mixture was hydrogenated again in the presence of 3 g of palladium-on-charcoal catalyst (10%) and 3 ml of a solution of thiophene in methanol (4%). After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was poured into water and the whole was basified with NaOH (50%). The product was extracted with dichloromethane and the extract was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CH₂Cl₂ / CH₃OH 95:5). The eluent of the desired fraction was evaporated and the residue was converted into the hydrochloride salt in 2-propanone by

adding 2-propanol saturated with HCl. The salt was filtered off and dried, yielding 46.9 g (69.3%) of (+)-(S)-6-fluoro-3,4-dihydro-N-(phenylmethyl)-2H-1-benzopyran-2-methanamine hydrochloride; mp. 210.7°C; $[\alpha]_D^{20} = +92.63^\circ$ (conc. = 0.1% in CH₃OH) (interm. 7).

5 In a similar way there were also prepared :

(S)-3,4-dihydro-N-(phenylmethyl)-2H-1-benzopyran-2-methanamine (interm. 8);

(-)-(R)-6-fluoro-3,4-dihydro-N-(phenylmethyl)-2H-1-benzopyran-2-methanamine hydrochloride; mp. 210.4°C; $[\alpha]_D^{20} = -79.47^\circ$ (conc. = 0.1% in CH₃OH) (interm. 9);

(R)-3,4-dihydro-N-(phenylmethyl)-2H-1-benzopyran-2-methanamine (interm. 10); and

10 (±)-3,4-dihydro-2-methyl-N-(phenylmethyl)-2H-1-benzopyran-2-methanamine (interm. 11).

c) A mixture of 28 g of intermediate (10) and 300 ml of methanol was hydrogenated in the presence of 2 g of palladium-on-charcoal catalyst (10%). After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated,
15 yielding 18.2 g (100%) of (-)-(R)-3,4-dihydro-2H-1-benzopyran-2-methanamine as crude residue (interm. 12).

In a similar way there were also prepared :

(±)-2,3-dihydro-1,4-benzodioxine-2-methanamine (interm. 13);

(S)-3,4-dihydro-2H-1-benzopyran-2-methanamine (interm. 14);

20 (±)-6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanamine (interm. 15);

(±)-3,4-dihydro-6-methoxy-2H-1-benzopyran-2-methanamine (interm. 16); and

(±)-3,4-dihydro-2H-1-benzopyran-2-methanamine (interm. 17).

Example 3

25 a) A mixture of 34 g of ethyl 4-oxo-1-piperidinecarboxylate, 20 g of 2-pyrimidinamine, 8 drops of acetic acid and 103.5 ml of methylbenzene was stirred for 28 hours at reflux temperature using a water-separator. The reaction mixture was evaporated, yielding 50 g of ethyl 4-(2-pyrimidinylimino)-1-piperidinecarboxylate as a residue (interm. 18).

b) To a stirred and cooled (5-10°C) mixture of 50 g of intermediate (18) in 76 ml of
30 methanol were added portionwise 7.5 g of sodium tetrahydroborate. Upon completion, stirring was continued first for 45 minutes at room temperature and further for 3 hours at reflux temperature. After cooling, the reaction mixture was poured into water and the product was extracted twice with benzene. The combined extracts were washed with water, dried, filtered and evaporated. The residue was solidified in a mixture of 2,2'-
35 oxybispropane and 2-propanone. The product was filtered off and crystallized from benzene, yielding 7 g of ethyl 4-(2-pyrimidinylamino)-1-piperidinecarboxylate (interm. 19).

- c) A mixture of 7 g of intermediate (19) and 80.5 ml of hydrobromic acid solution (48%) was stirred for 2 hours at reflux temperature. The reaction mixture was evaporated and the residue was taken up in water. The whole was basified with a diluted sodium hydroxide solution, while cooling in an ice-bath. The product was extracted with dichloromethane and the extract was dried, filtered and evaporated. The residue was stirred in 2,2'-oxybispropane. The product was filtered off and converted into the hydrochloride salt in 2-propanol. The salt was filtered off and crystallized from ethanol, yielding 2 g of (\pm)-N-(4-piperidiny)-2-pyrimidinamine dihydrochloride hemihydrate; mp. 268.5°C (interm. 20).


10










Example 4

- a) 3 ml of N,N,N-trimethylbenzenemethanaminium hydroxide was added dropwise to a stirred mixture of 60 g (\pm)-3,4-dihydro-N-(phenylmethyl)-2H-1-benzopyran-2-methanamine in 350 ml of 2-propenenitrile. After stirring for 4 days at reflux temperature, the reaction mixture was cooled and poured into 1,1'-oxybisethane. The whole was filtered over diatomaceous earth and the filtrate was evaporated, yielding 21 g (28.6%) of (\pm)-3-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl](phenylmethyl)amino]propanenitrile as crude residue (interm. 21).
- b) A mixture of 21 g of intermediate (21) in 250 ml of methanol was hydrogenated in the presence of 5 g of Raney Nickel. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated, yielding 20 g (94%) of (\pm)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N-(phenylmethyl)-1,3-propanediamine as crude residue (interm. 22).
- c) A mixture of 10 g of intermediate (22), 4.2 g of 2-chloropyrimidine, 6 g of sodium carbonate and 100 ml of ethanol was stirred and heated for 18 hours. The reaction mixture was cooled and the solvent was evaporated. The residue was treated with water and the product was extracted with 1,1'-oxybisethane. The extract was dried, filtered and evaporated, yielding 11 g (88.5%) of (\pm)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N-(phenylmethyl)-N'-(2-pyrimidinyl)-1,3-propanediamine as a crude residue (interm. 23).

30

In a similar way there was also prepared :



Int. No.	R ⁷ , R ⁸	$ \begin{array}{c} \text{N}-\text{R}^1 \\ \diagup \quad \diagdown \\ -\text{C} \quad \text{N}-\text{R}^2 \\ \diagdown \quad \diagup \\ \text{R}^3 \end{array} $	Physical data
23	H, H		-
24	H, H		.2HCl
25	H, H		.HCl; mp. 230.1°C
26	H, H		-
27	7-CH ₂ CH ₃ , H		.2HCl.H ₂ O
28	H, H		-
29	H, H		-
30	H, H		-
31	H, H		.2HCl.1/2H ₂ O; mp. 189.6°C

Example 5


- a) To a stirred solution of 6 g of diphenyl cyanocarbonimidate in 50 ml of dichloromethane at room temperature were added portionwise 2.1 g of piperidine. Stirring was continued for 30 minutes at room temperature. The reaction mixture was evaporated and

the residue was crystallized from 2,2'-oxybispropane. The crystals were filtered off and dried, yielding 4.6 g (80.7%) of [phenoxy(1-piperidinyl)methylene]cyanamide; mp. 85.7 C (interm. 32).

In a similar way was also prepared :


- 5 O-phenyl-N'-cyano-N,N-dimethylcarbamimidate (interm. 33).
 b) A mixture of 4.0 g of (+)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-1,3-propanediamine, 4.2 g of intermediate (32) and 100 ml of methanol was stirred for 3 days at room temperature. The reaction mixture was evaporated and the residue was dissolved in dichloromethane. This solution was washed with an aqueous Na₂CO₃ solution (15%). The organic layer was separated, dried, filtered and evaporated. The residue was purified twice by column chromatography (silica gel ; CH₂Cl₂ / CH₃OH 95:5). The eluent of the desired fraction was evaporated and the residue was converted into the ethanedioate salt (1:1) in 2-propane. The salt was filtered off and recrystallized from methanol. The crystals were filtered off and dried, yielding 1.02 g (12.7%) of
 10 (±)-N'-cyano-N-[3-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-1-piperidinecarboximidamide ethanedioate (1:1); mp. 176.0°C (interm. 34).
 15 (±)-N'-cyano-N-[3-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-1-piperidinecarboximidamide ethanedioate (1:1); mp. 176.0°C (interm. 34).

In a similar way there were also prepared :



20

Int. No.	R ⁷ , R ⁸	X	A	-NR ² R ³	physical data
34	H, H	CH ₂	-NH-(CH ₂) ₃ -NH-		mp. 176.0°C ethanedioate (1:1)
35	6-F, H	CH ₂	-NH-(CH ₂) ₃ -NH-	-NH-CH ₂ -CH ₃	mp. 117.8°C
36	H, H	CH ₂	-NH-(CH ₂) ₃ -NH-	-NH-CH ₂ -CH ₃	mp. 147.9°C / ethanedioate (1:1)
37	H, H	O	-NH-(CH ₂) ₃ -NH-	-NH-CH ₂ -CH ₃	mp. 138.3°C / ethanedioate (1:1)
38	H, H	CH ₂		-NH-(CH ₂) ₂ -CH ₃	-

Int. No.	R ⁷ , R ⁸	X	A	-NR ² R ³	physical data
39	H, H	CH ₂	-NH-(CH ₂) ₃ -NH-	-NH-CH-(CH ₃) ₂	mp. 121.8 C
40	H, H	CH ₂	-NH-(CH ₂) ₃ -NH-	-NH-(CH ₂) ₂ -CH ₃	mp. 154.6°C / ethanedioate (1:1)
41	H, H	CH ₂	-NH-(CH ₂) ₃ -NH-	-N-(CH ₃) ₂	mp. 171.1°C ethanedioate (1:1)
42	H, H	CH ₂	-NH-(CH ₂) ₂ -NH-	-NH-CH ₃	mp. 158.0°C / HCl
43	H, H	CH ₂	-NH-(CH ₂) ₃ -NH-	-NH-CH ₂ -C≡CH	mp. 143.2°C
44	H, H	CH ₂	-NH-(CH ₂) ₃ -NH-	-NH-CH ₂ -CH=CH ₂	mp. 164.7°C ethanedioate (1:1)
45	7-CH ₃ , H	CH ₂	-NH-(CH ₂) ₃ -NH-	-N-(CH ₃) ₂	mp. 190.2°C ethanedioate (1:1)
46	6-F, H	CH ₂	-NH-(CH ₂) ₃ -NH-	-N-(CH ₃) ₂	mp. 173.2°C (-)-(R) ethanedioate (1:1) [α] _D ²⁰ = -53.67° (c = 1% in DMF)
47	7-CH ₂ CH ₃ , H	CH ₂	-NH-(CH ₂) ₃ -NH-	-N-(CH ₃) ₂	mp. 137.8°C ethanedioate (1:1)
48	7-CH ₂ CH ₃ , H	CH ₂	-NH-(CH ₂) ₃ -NH-	-NH-CH ₂ -CH ₃	mp. 91.7°C
49	7-CH ₂ CH ₃ , H	CH ₂	-NH-(CH ₂) ₃ -NH-	-N-(CH ₃) ₂	mp. 163.3°C ethanedioate (1:2)
50	H, H	CH ₂		-NH-CH ₂ -CH ₃	mp. 118.5°C

Example 6

A mixture of 3.1 g (±)-N''-cyano-N-[3-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-N'-ethylguanidine in a solution of 10 ml hydrochloric acid in
 5 2-propanol and 50 ml methanol was stirred and refluxed for 30 minutes. The solvent

was evaporated. The residue was dissolved in water and this mixture was alkalized with aqueous NaOH (10%). This mixture was extracted with CH₂Cl₂. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/(NH₃) 90:10). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:2) with 2-propanol saturated with HCl. The salt was filtered off and recrystallized from 2-propanol. The crystals were filtered off and dried, yielding 2.95 g (±)-N-[[[3-[[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]amino]-(ethylamino)methylene]urea dihydrochloride; mp. 182.2°C (interm. 51).

In a similar manner there was also prepared :

(±)-N-[[[2-[[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]ethyl]amino]-(ethylamino)methylene]urea dihydrochloride; mp. 200.2°C (interm 52).


Example 7














a) A mixture of 12.5 g of 3,4-dihydro-N-(phenylmethyl)-2H-1-benzopyran-2-methanamine, 9 g of 4-bromobutanenitrile, 200 ml of N,N-dimethylformamide and 10 ml of N,N-diethylethanamine was stirred for 72 hour at room temperature. The reaction mixture was evaporated and the residue was partitioned between 1,1'-oxybisethane and water. The organic layer was separated, dried, filtered and evaporated, yielding 11 g (68.7%) of (±)-4-[[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl](phenylmethyl)amino]-butanenitrile (interm. 53).

b) A mixture of 11 g of intermediate (53) and 250 ml tetrahydrofuran was hydrogenated in the presence of 2 g of Raney Nickel. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was partitioned between 1,1'-oxybisethane and water. The organic layer was separated, dried, filtered and evaporated, yielding 10 g (90.6%) of (±)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N-(phenylmethyl)-1,4-butanedi-amine (interm. 54).

c) A mixture of 10 g of intermediate (54), 5.4 g of 2-chloropyrimidine, 8 g of sodium carbonate and 250 ml of ethanol was stirred for 18 hours at reflux temperature. The reaction mixture was evaporated and the residue was partitioned between 1,1'-oxybisethane and water. The organic layer was separated, dried, filtered and evaporated, yielding 10.4 g (83.3%) of (±)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N-(phenylmethyl)-N'-(2-pyrimidinyl)-1,4-butanedi-amine (interm. 55).

In a similar way there were also prepared :




Int. No.	R ⁷ , R ⁸	X	R ⁴	n		physical data
55	H, H	CH ₂	H	4		-
56	H, H	CH ₂	H	2		(S)
57	6-F, H	CH ₂	H	2		$[\alpha]_D^{20} = 54.79^\circ$ (c = 1% in CH ₃ OH) mp. 155.9°C / (+)-(S) 2HCl.1/2 H ₂ O
58	H, H	CH ₂	H	2		(R)
59	6-F, H	CH ₂	H	2		mp. 173.8°C (-)-(R) 2HCl
60	H, H	O	H	2		-
61	H, H	CH ₂	H	2		mp. 175.6°C 2HCl .1/2 H ₂ O
62	H, H	CH ₂	CH ₃	2		-
63	H, H	CH ₂	H	5		-
64	H, H	CH ₂	H	4		(R) . HCl
65	6-F, H	CH ₂	H	2		mp. 219.5°C (-)-(R).2HCl
66	H, H	CH ₂	H	5		(R) . HCl

Example 8

a) A mixture of 18 g of intermediate (12), 60 g of 2-propenenitrile and 400 ml of ethanol was stirred for 4 hours at reflux temperature. The reaction mixture was evaporated and the residue was dried, yielding 20 g (84%) of (-)-(R)-3-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propanenitrile (interm. 67).

b) A mixture of 20 g intermediate (67) and 300 ml of methanol was hydrogenated in the presence of 5 g of Raney Nickel. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated, yielding 21 g (100%) of (-)-(R)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-1,3-propanediamine as crude residue (interm. 68).

In a similar way there were also prepared :



15

Int. No.	R ⁷ , R ⁸	X
68	H, H	CH ₂
69	6-F, H	CH ₂
70	H, H	O
71	H, H	CH ₂
72	6-OCH ₃ , H	CH ₂
73	H, H	CH ₂

Example 9

a) To a stirred mixture of 38.6 g of N,N-dibenzyl-N'-[(3,4-dihydro-2H-1-benzopyran-2-yl)-1,2-ethanediamine, 1.2 g of N,N-dimethyl-4-pyridinamine and 300 ml of acetonitrile at room temperature, was added dropwise a solution of 24 g of bis(1,1-dimethylethyl) dicarbonate in 50 ml of acetonitrile. After stirring for 3 hours, the reaction mixture was evaporated and the residue was diluted with water. The product was extracted with 1,1'-oxybisethane and the extract was dried, filtered and evaporated, yielding 50 g (100%) of (±)-1,1-dimethylethyl [2-[bis(phenylmethyl)amino]ethyl] [(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]carbamate as crude residue (interm. 74).

- b) A mixture of 14.0 g of intermediate (74) and 150 ml of methanol was hydrogenated in the presence of 2 g of palladium-on-charcoal catalyst (10%). After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography (silica gel ; CH₂Cl₂ / CH₃OH(NH₃) 95:5). The eluent of the desired fraction was evaporated, yielding 1.22 g of (±)-1,1-dimethylethyl (2-aminoethyl) [(3,4-dihydro-2H-1-benzopyran-2-yl)-methyl]carbamate (interm. 75).
- 5 c) To a mixture of 7.0 g of intermediate (75) and 100 ml of trichloromethane were added 3.3 g of dimethyl cyanocarbonimidodithionate. After stirring for 48 hours at reflux
- 10 temperature, the reaction mixture was evaporated. The residue was purified by column chromatography (silica gel ; CH₂Cl₂ / CH₃OH 99:1). The eluent of the desired fraction was evaporated, yielding 9.09 g (96.5%) of (±)-1,1-dimethylethyl [2-[(cyanoimino)-(methylthio)methyl]amino]ethyl [(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]carbamate (interm. 76).
- 15 d) To a mixture of 18 g of intermediate (76) and 150 ml of ethanol were added 40 ml of an aqueous solution of ethanamine (70%). After stirring for 16 hours at reflux
- 20 temperature, the reaction mixture was evaporated and the residue was dissolved in dichloromethane. This solution was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CH₂Cl₂ / CH₃OH 95:5). The eluent of the desired fraction was evaporated and the residue was solidified from 2,2'-oxybispropane, yielding 13.9 g (77.2%) of (±)-1,1-dimethylethyl [2-[(cyanoimino) (ethylamino)methyl]amino]ethyl [(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]carbamate; mp. 115.4°C (interm. 77).
- 25 e) A mixture of 6 g of intermediate (77), 20 ml of 2-propanol saturated with HCl and 200 ml of methanol was stirred for 30 minutes at reflux temperature. The reaction
- 30 mixture was evaporated and the residue was crystallized from methanol. The product was filtered off and washed with methanol and 2,2'-oxybispropane, yielding 4.3 g (73%) of (±)-N-[[[2-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]ethyl]amino] (ethylamino)methylene]urea dihydrochloride; mp. 200.2°C (interm. 78).

B. Preparation of the finals

Example 10

- A mixture of 7.4 g of N¹-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-1,2-ethane-diamine, 4.1 g 2-chloropyrimidine, 4.2 g of sodium carbonate and 50.6 ml of ethanol
- 35 was stirred for 4 hours at reflux temperature. The reaction mixture was evaporated. The residue was purified by column chromatography (silica gel ; CHCl₃ / CH₃OH 90:10). The eluent of the desired fraction was evaporated and the residue was converted into the

hydrochloride salt in 2-propanol. The salt was filtered off and dried in vacuo, yielding 4.4 g (33.3%) of (\pm) -N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(2-pyrimidinyl)-1,2-ethanediamine dihydrochloride hemihydrate; mp. 192.7 C (comp. 1).

5 Example 11

A mixture of 8.5 g of 3,4-dihydro-2H-benzopyran-2-carbonyl chloride, 30 ml of N,N-dimethylacetamide and 100 ml of 2,2'-oxybispropane was hydrogenated in the presence of 2 g of palladium-on-charcoal catalyst (10%) and 2 ml of a solution of thiophene in methanol (4%). After the calculated amount of hydrogen was taken up, the catalyst was
10 filtered off and the filtrate was added to a mixture of 5 g of (\pm) -N¹-(2-pyrimidinyl)-1,2-propanediamine and 150 ml of methanol. The whole was hydrogenated in the presence of 2 g of palladium-on-charcoal catalyst (10%) and 5 g of potassium acetate. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in 1,1'-oxybisethane, washed with an
15 aqueous NaOH solution, dried, filtered and evaporated. The residue was converted into the ethanedioate salt (1:2) in 2-propanone. The salt was filtered off and dried in vacuo at 60°C, yielding 8.7 g (55.1%) of (\pm) -N¹-(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N²-(2-pyrimidinyl)-1,2-propanediamine ethanedioate(1:2), mp. 150.2°C (comp. 119).

20

Example 12

A mixture of 4.8g 6-bromo-3,4-dihydro-2H-1-benzopyran-2-carboxaldehyde and 3.1g N-2-pyrimidinyl-1,3-propanediamine in 200ml methanol was hydrogenated with 2g platinum on activated carbon (5%) as a catalyst in the presence of 2ml of a solution of
25 thiophene in methanol (4%). After uptake of H₂, the catalyst was filtered off. The filtrate was evaporated. The residue was dissolved in 2-propanone and converted into the ethanedioic acid salt (1:2). The salt was filtered off and recrystallized from ethanol/water. The crystals were filtered off and dried, yielding 2.7g (18.8%) (\pm) -N-[(6-bromo-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(2-pyrimidinyl)-1,3-
30 propanediamine ethanedioate(1:2); mp. 215.3°C (comp. 20).

Example 13

A mixture of 3 g N-2-pyrimidinyl-1,3-propanediamine in 150 ml methanol and 10 ml of a solution of hydrochloric acid in 2-propanol was hydrogenated with 2 g palladium on
35 activated charcoal (5%) as a catalyst. After uptake of H₂, the catalyst was filtered off. A solution of 4.8 g 6-bromo-3,4-dihydro-2H-1-benzopyran-2-carboxaldehyde in 100ml methanol was added to the filtrate. 10 g Potassium acetate was added and the resulting mixture was hydrogenated with 2 g platinum on activated charcoal (5%) as a catalyst, in

the presence of 2 ml of a solution of thiophene in methanol (4%). After uptake of H₂, the catalyst was filtered off. The solvent was evaporated and the residue was dissolved in a mixture of H₂O/CH₂Cl₂. This solution was alkalized with NaOH. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was dissolved in 2-propanone and converted into the ethanedioic acid salt (1:2). The salt was filtered off and dried. This fraction was recrystallized from ethanol/water. The crystals were filtered off and dried, yielding 3.5 g (31.2%) of (±)-N-[(6-bromo-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(1,4,5,6-tetrahydro-2-pyrimidinyl)-1,3-propanediamine ethanedioate(1:2); mp. 204.8°C (comp. 56).

Example 14

A mixture of 7.9 g of 3,4-dihydro-2H-1-benzopyran-2-methanol 4-methylbenzenesulfonate(ester), 4.5 g N-(4-piperidinyl)-2-pyrimidinamine, 5.3 g of sodium carbonate and 100 ml of 4-methyl-2-pentanone was stirred overnight at reflux temperature. The reaction mixture was evaporated and the residue was diluted with water. The product was extracted with dichloromethane and the extract was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂ 100%). The eluent of the desired fraction was evaporated and the residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 28 g (98.8%) of (+)-N-[1-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-4-piperidinyl]-2-pyrimidinamine; mp. 141.9°C (comp. 128).

Example 15

A mixture of 8.4 g of (-)-(R)-N-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)methyl-N-phenylmethyl-N'-(2-pyrimidinyl)-1,2-ethanediamine and 150 ml methanol was hydrogenated in the presence of 2 g of palladium-on-charcoal catalyst (10%). After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂ / CH₃OH 90:10). The eluent of the desired fraction was evaporated and the residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 3.5 g (55.1%) of (-)-(R)-N-[(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(2-pyrimidinyl)-1,2-ethanediamine; mp. 103.2°C [α]_D²⁰ = -76.58° (conc. = 1% in CH₃OH) (comp. 46).

Example 16

A mixture of 3.6 g of (-)-(R)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(2-pyrimidinyl)-1,3-propanediamine dihydrochloride hemihydrate in 150 ml of methanol and 20 ml of 2-propanol saturated with HCl was hydrogenated in the presence

- of 1.5 g of palladium-on-charcoal catalyst (2%). After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The product was crystallized from acetonitrile, filtered off and dried, yielding 2.7 g (74.0%) of (-)-(R)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(1,4,5,6-tetrahydro-2-pyrimidinyl)-1,3-propanediamine dihydrochloride hemihydrate; mp. 200.2°C
5 $[\alpha]_D^{20} = -60.97^\circ$ (conc. = 1% in CH₃OH) (comp. 62).

Example 17

- A mixture of 7.8 g of N-(3,4-dihydro-2H-1-benzopyran-2-yl)methyl-N-phenylmethyl-N'-(2-pyrimidinyl)-1,3-propanediamine, 200 ml methanol and 10 ml of 2-propanol
10 saturated with HCl was hydrogenated in the presence of 2 g of palladium-on-charcoal catalyst (5%). After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was converted into the dihydrochloride salt in 2-propanol by adding 2-propanol saturated with hydrochloric acid. The
15 salt was filtered off and dried, yielding 2.9 g (38.0%) of (+)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(1,4,5,6-tetrahydro-2-pyrimidinyl)-1,3-propanediamine dihydrochloride ; mp. 227.0 °C (comp. 95).

Example 18

- A solution of 6.9 g of (+)-N-[(3,4-dihydro-6-methoxy-2H-1-benzopyran-2-yl)methyl]-N'-(2-pyrimidinyl)-1,3-propanediamine in 50 ml of dichloromethane was added
20 dropwise to a mixture of 150 ml of a boron tribromide solution in dichloromethane (1M) and 250 ml dichloromethane, stirred under a nitrogen atmosphere at 0°C. The reaction mixture was stirred for 2 hours at room temperature. The resulting precipitate was
25 filtered off and stirred in a mixture of 150 g of ice, 42 g of sodium chloride and 175 ml of NH₄OH. Dichloromethane was added and the whole was filtered over diatomaceous earth. The layers were separated and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CH₂Cl₂ / CH₃OH/(NH₃) 95:5).
30 The eluent of the desired fraction was evaporated and the residue was converted into the ethanedioate salt in 2-propanone. The salt was filtered off and dried in vacuo at 60°C, yielding 3.0 g (28.9%) of (+)-3,4-dihydro-2-[[[3-(2-pyrimidinylamino)propyl]-amino]methyl]-2H-1-benzopyran-6-ol ethanedioate (1:2); mp. 170.0 °C (comp. 49).

Example 19

A mixture of 2.6 g of (+)-N"-cyano-N-[3-[[[3,4-dihydro-2H-1-benzopyran-2-yl)-methyl]amino]propyl]-N'-(1-methylethyl)guanidine in 20 ml of hydrochloric acid 6N

was stirred for 2 hours at reflux temperature. The reaction mixture was evaporated and the residue was dissolved in 10 ml of methanol. This solution was filtered and the filtrate was evaporated. The oily residue was dissolved in 10 ml of ethanol. The mixture was filtered and the filtrate was evaporated, yielding 1.32 g (44.4%) of (+)-N-[3-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-N'-(1-methylethyl)-guanidine dihydrochloride; mp. 97.5°C (comp. 150).

Example 20

2.3g (±)-N-[(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-1,3-propanediamine and 1.6g iodine monochloride were dissolved in 50ml acetic acid. This solution was stirred and refluxed overnight. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 99:1 upgrading to 95:5). Two desired fractions were collected and the solvent was evaporated. The residue (±50% pure) was recrystallized from ethanol. The crystals were filtered off and dried, yielding 0.650g (20.1%) of (±)-N-[(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(5-iodo-2-pyrimidinyl)-1,3-propanediamine monohydrochloride; mp. 228.2°C (comp. 155).

Example 21


A mixture of 0.250g palladium on activated carbon 10% in 50ml methanol was stirred under vacuum and rinsed with H₂. 5 ml of 2-propanol saturated with HCl was added. A solution of 0.5g (±)-3,4-dihydro-2-[[[3-(2-pyrimidinylamino)propyl]amino]methyl]-2H-1-benzopyran-6-carbonitrile dihydrochloride hemihydrate in 5 ml methanol was added dropwise. The reaction mixture was hydrogenated while stirring for 2 hours. After uptake of H₂, the mixture was filtered over dicalite. The filter residue was washed with CH₃OH. The filtrate was evaporated and the residue was stirred in 10ml CH₃OH, filtered over a pleated paper filter and washed with 5ml CH₃OH. The filtrate was evaporated. The residue was stirred in 10 ml 2-propanone, then filtered over a glass filter. The filter residue was dried, yielding 0.427g (82.2%); mp. 240.1°C (comp. 102).

Example 22

50 ml Methylbenzene was added to 4.3 g (±)-methyl 8-ethynyl-6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylate, then evaporated. The residue was dissolved in 100 ml methylbenzene and this solution was cooled to -70°C. A solution of 25 ml hydrobis(2-methylpropyl)aluminum hydride in methylbenzene (20%) was added dropwise. The reaction mixture was stirred for 1 hour at -70°C. 10 ml Methanol was added dropwise

- and the temperature was allowed to reach room temperature. The reaction mixture was poured out into 150 ml water and extracted with diethyl ether. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was dissolved in methanol and 1.95 g *N*-(2-pyrimidinyl)-1,3-propanediamine was added. This mixture was hydrogenated at room temperature with 1 g palladium on activated carbon (10%) as a catalyst in the presence of a solution of 4 ml of thiophene (4%). After uptake of H₂, the catalyst was filtered off. The filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 95:5 upgrading to 90:10). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in 80 ml 2-propanone and converted into the ethanedioic acid salt (1:1). The salt was filtered off, washed with 2-propanone and 2,2'-oxybispropane, then dried, yielding 4.3g (63.1%) of (±)-*N*-[(8-ethyl-6-fluoro-3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]-*N*'-2-pyrimidinyl-1,3-propanediamine ethanedioate (1:2); mp. 210.8°C (comp. 54).
- 15 All compounds listed in Tables 1 to 5 were prepared following methods of preparation described in Examples 10 to 22, as indicated in the column Ex.No..

Table 1




Co. No.	Ex. No.	R ⁷	R ⁸	X	s	physical data
1	10	H	H	CH ₂	2	mp. 192.7°C/. 2 HCl .1/2 H ₂ O
2	10	H	H	CH ₂	3	mp. 193.4°C/ [α] _D ²⁰ = -63.46° (c = 1% in CH ₃ OH). (-)-(R).2 HCl . 1/2H ₂ O
3	10	6-F	H	CH ₂	3	mp. 139.9°C/ .2 HCl . 1/2H ₂ O
4	10	H	H	O	3	-
5	10	H	H	CH ₂	3	mp. 223.2°C/ [α] _D ²⁰ = 48.63° (c = 0.1% in CH ₃ OH)/ (+)-(S) . HCl
6	10	6-O-CH ₃	H	CH ₂	3	mp. 190.6°C/. HCl
7	10	7-CH ₃	H	CH ₂	3	mp. 212.0°C/ ethanedioate (1:2)

Co. No.	Ex. No.	R ⁷	R ⁸	X	s	physical data
8	10	7-C ₂ H ₅	H	CH ₂	3	mp. 141.4 °C / [α] _D ²⁰ = 67.48° (c = 1% in CH ₃ OH) / (+)-(S) .2 HCl . 1/2 H ₂ O
9	10	7-C ₂ H ₅	H	CH ₂	3	mp. 154.9°C / [α] _D ²⁰ = -69.37° (c = 1% in CH ₃ OH) / (-)-(R) .2 HCl
10	11	H	H	-	3	mp. 145.8°C / .2 HCl . 1/2 H ₂ O
11	11	6-F	H	CH ₂	6	mp. 170.3°C / .2 HCl
12	11	6-F	H	CH ₂	3	mp. 197.5°C / (+)-(S) .2 HCl
13	11	6-F	H	CH ₂	3	mp. 200.9°C / (-)-(R) .2 HCl
14	11	6-F	H	CH ₂	4	mp. 171.1°C / [α] _D ²⁰ = -64.54° (c = 1% in CH ₃ OH) / (-)-(R) .2 HCl
15	11	6-F	H	CH ₂	4	mp. 177.4°C / [α] _D ²⁰ = 66.26° (c = 1% in CH ₃ OH) / (+)-(S) .2 HCl
16	11	7-C ₂ H ₅	H	CH ₂	3	mp. 125.5°C / .2 HCl . 1/2 H ₂ O
17	11	7-C ₂ H ₅	H	CH ₂	5	mp. 177.1°C / .2 HCl
18	11	7-C ₂ H ₅	H	CH ₂	4	mp. 140.1°C / .2 HCl
19	11	H	H	O	4	mp. 208.1°C / ethanedioate (1:1)
20	12	6-Br	H	CH ₂	3	mp. 215.3°C / ethanedioate (1:2)
21	12	6-CH ₃	H	CH ₂	3	mp. 207.1°C / ethanedioate (1:1)
22	12	7-F	H	CH ₂	3	mp. 217.3°C / ethanedioate (1:1)
23	12	5-CH ₃	7-CH ₃	CH ₂	3	mp. 186.6°C / .2 HCl
24	12	H	8-OCH ₃	CH ₂	3	mp. 216.1°C / .2 HCl
25	12	H	H	CH ₂	9	mp. 159.7°C / 2 HCl . 1/2 H ₂ O
26	12	H	H	CH ₂	8	mp. 152.9°C / 2 HCl
27	12	7-OCH ₃	H	CH ₂	3	ethanedioate (1:1)
28	12	H	H	CH ₂	10	mp. 164.9°C / .2 HCl
29	12	H	H	CH ₂	7	mp. 152.4°C / .2 HCl
30	12	6-F	8-Br	CH ₂	3	mp. 145.0°C
31	12	H	8-CH ₃	CH ₂	3	ethanedioate (1:2)
32	12	5-OCH ₃	H	CH ₂	3	mp. 219.9°C / ethanedioate (1:1)
33	12	H	8-CH ₃	CH ₂	3	mp. 219.3°C / ethanedioate (1:1)
34	12	7-CH(CH ₃) ₂	H	CH ₂	3	mp. 127.0°C / .2 HCl . H ₂ O
35	12	7-C ₄ H ₉	H	CH ₂	3	mp. 170.9°C / .2 HCl . H ₂ O

Co. No.	Ex. No.	R ⁷	R ⁸	X	s	physical data
36	12	7-C ₃ H ₇	H	CH ₂	3	. 2 HCl . 2 H ₂ O
37	12	7-C(CH ₃) ₃	H	CH ₂	3	. 2 HCl
38	12	7-CH ₃	8-CH ₃	CH ₂	3	. 2 HCl
39	12	H	H	CH ₂	3	mp. 120.9°C/ [α] _D ²⁰ = -15.78° (c = 1% in methanol)/ (-)-(R) cyclohexylsulfamate (1:2)
40	12	6-F	8-NHCOCH ₃	CH ₂	3	mp. 172.9°C/ ethanedioate (1:2)
41	14	6-CN	H	CH ₂	3	mp. 175.1°C/ . 2 HCl . 1/2 H ₂ O
42	14	6-Br	8-NO ₂	CH ₂	3	mp. 195.1°C/ . 2 HCl
43	15	H	H	CH ₂	2	mp. 201.7°C/ [α] _D ²⁰ = 89.14° (c = 1% in CH ₃ OH)/ (+)-(S) . 2 HCl
44	15	6-F	H	CH ₂	2	mp. 102.9°C/ [α] _D ²⁰ = 80.32° (c = 1% in CH ₃ OH)/ (+)-(S)
45	15	H	H	CH ₂	2	mp. 204.5°C/ [α] _D ²⁰ = -63.45° (c = 0.5 % in DMF)/ (-)-(R) . 2 HCl
46	15	6-F	H	CH ₂	2	mp. 103.2°C/ [α] _D ²⁰ = -76.58° (conc. = 1% in CH ₃ OH)/ (-)-(R)
47	15	H	H	CH ₂	3	mp. 142.9°C/ . 2 HCl . 1/2 H ₂ O
48	15	H	H	CH ₂	4	mp. 140.8°C/ . 2 HCl . H ₂ O
49	18	6-OH	H	CH ₂	3	mp. 170.0°C/ ethanedioate (1:2)
50	18	H	8-OH	CH ₂	3	mp. 170.5°C/ . 2 HCl
51	18	7-OH	H	CH ₂	3	-
52	18	5-OH	H	CH ₂	3	mp. 139.1°C/ ethanedioate (1:2)
53	21	H	8-NH ₂	CH ₂	3	mp. 270.7°C/ . 3 HCl . H ₂ O
54	22	6-F	8-CH ₂ -CH ₃	CH ₂	3	mp. 210.8°C/ ethanedioate (1:2)

Table 2




Co No	Ex No	R ⁷	R ⁸	X	s	physical data
55	10	6-OCH ₃	H	CH ₂	3	mp. 199.9°C/. 2 HBr
56	13	6-Br	H	CH ₂	3	mp. 204.8°C/ ethanedioate (1:2)
57	16	H	H	CH ₂	2	mp. 216.7°C/. 2 HCl
58	16	H	H	CH ₂	2	mp. 197.8°C/ [α] _D ²⁰ = 53.59° (c = 0.5% in CH ₃ OH)/ (+)-(S). 2 HCl
59	16	H	H	CH ₂	2	mp. 199.2°C/ [α] _D ²⁰ = -52.66° (c = 0.5% in DMF)/ (-)-(R). 2 HCl
60	16	6-F	H	CH ₂	2	mp. 215.1°C/ [α] _D ²⁰ = 68.31° (c = 1% in CH ₃ OH)/ (+)-(S). 2 HCl
61	16	6-F	H	CH ₂	2	mp. 213.9°C/ [α] _D ²⁰ = -64.80° (c = 1% in CH ₃ OH)/ (-)-(R). 2 HCl
62	16	H	H	CH ₂	3	mp. 200.2°C/ [α] _D ²⁰ = -60.97° (c = 1% in CH ₃ OH) (-)-(R) . 2HCl . 1/2 H ₂ O
63	16	6-F	H	CH ₂	3	mp. 226.3°C/. 2 HCl
64	16	H	H	O	3	mp. 164.7°C/. 2 HCl
65	16	H	H	CH ₂	3	mp. 162.0°C/ [α] _D ²⁰ = 65.83° (c = 1% in CH ₃ OH) (+)-(S). 2 HCl . H ₂ O
66	16	H	H	-	3	mp. 167.9°C/. 2 HCl . 1/2 H ₂ O
67	16	7-CH ₃	H	CH ₂	3	mp. 216.4°C/. ethanedioate (1:2)
68	16	6-F	H	CH ₂	6	mp. 201.1°C/. 2 HCl
69	16	6-F	H	CH ₂	3	mp. 228.9°C/ [α] _D ²⁰ = 65.47° (c = 1% in CH ₃ OH) (+)-(S) . 2 HCl










Co No	Ex No	R ⁷	R ⁸	X	s	physical data
70	16	6-F	H	CH ₂	3	mp. 228.9°C/ [α] _D ²⁰ = -65.45° (c = 1% in CH ₃ OH) (-)-(R) . 2 HCl
71	16	6-F	H	CH ₂	4	mp. 203.2°C/ [α] _D ²⁰ = 65.81° (+)-(S) . 2 HCl
72	16	7-F	H	CH ₂	3	mp. 221.2°C/ ethanedioate (1:2)
73	16	7-CH ₂ -CH ₃	H	CH ₂	3	mp. 155.3°C/ . 2 HCl. 1/2 H ₂ O
74	16	5-CH ₃	7-CH ₃	CH ₂	3	mp. 195.4°C/ . 2 HCl
75	16	H	H	CH ₂	9	mp. 154.6°C/ . 2 HCl
76	16	H	8-OCH ₃	CH ₂	3	mp. 130.0°C/ . 2 HCl. 1/2 H ₂ O
77	16	H	H	CH ₂	8	mp. 139.5°C/ . 2 HCl. 1/2 H ₂ O
78	16	H	7-OCH ₃	CH ₂	3	mp. 213.6°C/ ethanedioate (1:2)
79	16	H	H	CH ₂	10	mp. 132.3°C/ . 2 HCl. 1/2 H ₂ O
80	16	H	H	CH ₂	7	mp. 113.0°C/ . 2 HCl. 1/2 H ₂ O
81	16	7-CH ₂ -CH ₃	H	CH ₂	4	mp. 157.2°C/ . 2 HCl
82	16	7-CH ₂ -CH ₃	H	CH ₂	5	mp. 125.1°C/ . 2 HCl
83	16	6-OH	H	CH ₂	3	mp. 241.3°C/ . 2 HCl
84	16	H	8-CH ₃	CH ₂	3	mp. 183.8°C/ ethanedioate (1:2)
85	16	5-OCH ₃	H	CH ₂	3	mp. 183.2°C/ ethanedioate (1:2)
86	16	7-CH(CH ₃) ₂	H	CH ₂	3	mp. 171.0°C/ . 2 HCl. 1/2 H ₂ O
87	16	7-C ₄ H ₉	H	CH ₂	3	mp. 178.2°C/ . 2 HCl
88	16	7-C ₃ H ₇	H	CH ₂	3	mp. 161.2°C/ . 2 HCl. 1/2 H ₂ O
89	16	7-C(CH ₃) ₃	H	CH ₂	3	mp. 191.5°C/ . 2 HCl . H ₂ O
90	16	7-CH ₃	8-CH ₃	CH ₂	3	mp. 202.7°C/ . 2 HCl . H ₂ O
91	16	H	H	CH ₂	3	mp. 165.9°C/ [α] _D ²⁰ = -26.40° (c = 1% in methanol)/ (-)-(R) cyclohexylsulfamate (1:2)
92	16	7-C ₂ H ₅	H	CH ₂	3	mp. 172.9°C/[α] _D ²⁰ = -76.83° (c=1% in methanol)/ (-)-(R) . 2 HCl
93	16	6-F	8-NHCOCH ₃	CH ₂	3	mp. 202.2°C/ ethanedioate (1:2)
94	16	6-F	8-C ₂ H ₅	CH ₂	3	mp. 204.1°C/ ethanedioate (1:2)
95	17	H	H	CH ₂	3	mp. 227.0°C/ . 2 HCl
96	17	H	H	O	2	mp. 220.8°C/ . 2 HCl

Co No	Ex No	R ⁷	R ⁸	X	s	physical data
97	17	H	H	CH ₂	4	mp. 96.2°C/ . 2 HCl . 3/2 H ₂ O
98	17	H	H	CH ₂	5	mp. 157.5°C/ . 2 HCl . 1/2 H ₂ O
99	17	H	H	CH ₂	4	mp. 117.5°C/ [α] _D ²⁰ = -62.87° (c = 1% in CH ₃ OH) (-)-(R) 2 HCl . 1/2 H ₂ O
100	17	H	H	CH ₂	5	mp. 191.8°C/ [α] _D ²⁰ = -59.92° (c = 1% in CH ₃ OH) (-)-(R) 2 HCl . 1/2 H ₂ O
101	17	6-F	H	CH ₂	4	mp. 209.5°C/ [α] _D ²⁰ = -63.68° (-)-(R) 2 HCl
102	21	6-CH ₂ -NH ₂	H	CH ₂	3	mp. 240.1°C/ 3 HCl . 3/2 H ₂ O

Table 3













































5

Co. No.	Ex. No.	R ⁷	R ⁸	X	-CH ₂ -A		physical data
103	10	H	H	CH ₂			mp. 264.2°C/ . 2 HCl
104	10	H	H	CH ₂			mp. 219.2°C/ . 2 HCl
105	10	H	H	CH ₂			mp. 121.6°C
106	10	6-F	H	CH ₂			mp. 201.0°C/ . 2 HCl

Co. No.	Ex. No.	R ⁷	R ⁸	X	-CH ₂ -A	$\begin{array}{c} \text{N}-\text{R}^1 \\ \diagup \\ \text{C} \\ \diagdown \\ \text{N}-\text{R}^2 \\ \\ \text{R}^3 \end{array}$	physical data
107	10	H	H	CH ₂			mp. 220.4°C . 2 HCl. 1/2 H ₂ O trans
108	10	H	H	CH ₂			mp. 243.2°C/ . 2 HCl cis
109	10	H	H	CH ₂			mp. 130.4°C H ₂ SO ₃ (1:1)
110	10	H	H	CH ₂			mp. 158.5°C ethanedioate (1:1)
111	10	H	H	CH ₂			mp. 121.1°C ethanedioate (1:2)
112	10	H	H	CH ₂			mp. 179.8°C/ ethanedioate (1:2)
113	10	H	H	CH ₂			mp. 192.5°C ethanedioate (1:1)
114	10	H	H	CH ₂			mp. 127.8°C
115	10	H	H	CH ₂			. HCl . 1/2 H ₂ O
116	10	7-C ₂ H ₅	H	CH ₂			mp. 219.8°C ethanedioate (1:2)
117	11	H	H	CH ₂			liquid

Co. No.	Ex. No.	R ⁷	R ⁸	X	-CH ₂ -A	$\begin{array}{c} \text{N}-\text{R}^1 \\ \diagup \\ \text{C} \\ \diagdown \\ \text{N}-\text{R}^2 \\ \\ \text{R}^3 \end{array}$	physical data
118	11	H	H	CH ₂			mp. 140.1°C / (-)-(R) [α] _D ²⁰ = -70.68° (c = 1% in CH ₃ OH)
119	11	H	H	CH ₂			mp. 150.2°C ethanedioate (1:2)
120	12	H	H	CH ₂			mp. 246.6°C ethanedioate (1:1)
121	12	H	H	CH ₂			mp. 202.5°C / . 2 HCl
122	12	H	H	CH ₂			mp. 120.6°C (B)
123	12	H	H	CH ₂			mp. 254.9°C / . 2 HCl (A)
124	13	H	H	CH ₂			mp. 220.2°C ethanedioate (1:2)
125	14	H	H	O			mp. 252.4°C ethanedioate (1:1)
126	14	H	H	O			mp. 218.1°C / . 2 HCl
127	14	H	H	O			mp. 205.4°C . 2HCl . 1/2 H ₂ O
128	14	H	H	CH ₂			mp. 141.9°C

Co. No.	Ex. No.	R ⁷	R ⁸	X	-CH ₂ -A		physical data
129	15	H	H	CH ₂			mp. 226.0°C / . 2 HCl
130	15	H	H	CH ₂			mp. 165.8°C . 2 HCl . H ₂ O
131	15	6-F	H	CH ₂			mp. 242.1°C / (-)-(R) . 2 HCl [α] _D ²⁰ = -72.75° (c = 1% in CH ₃ OH)
132	15	H	H	CH ₂			mp. 254.0°C / . 2. HCl
133	15	7-C ₂ H ₅	H	CH ₂			mp. 199.2°C . 2 HCl . 1/2 H ₂ O
134	15	H	H	CH ₂			mp. 190.6°C/ ethanedioate (1:2)
135	15	H	H	CH ₂			mp. 190.3°C/ ethanedioate (1:2)
136	16	H	H	CH ₂			mp. 239.8°C . 2 HCl . 1/2 H ₂ O
137	16	H	H	CH ₂			mp. > 300.0°C . 2 HCl
138	16	H	H	CH ₂			mp. 172.7°C / . 2 HCl

Co. No.	Ex. No.	R ⁷	R ⁸	X	-CH ₂ -A		physical data
139	16	H	H	CH ₂			mp. 230.0°C (decom.) [α] _D ²⁰ = -57.20° (c = 0.7% in CH ₃ OH) (-)-(R) . 2HCl. 3/2 H ₂ O
140	16	H	H	CH ₂			mp. 175.9°C . 2 HCl. 1/2 H ₂ O trans
141	16	H	H	CH ₂			mp. 196.7°C . 2 HCl. 1/2 H ₂ O cis
142	16	H	H	CH ₂			mp. 200.4°C . 2 (COOH) ₂ . 1/2 H ₂ O
143	16	H	H	CH ₂			mp. 158.2°C ethanedioate (1:2)
144	16	H	H	CH ₂			mp. 281.3°C . 2 HCl trans
145	16	H	H	CH ₂			mp. 273.1°C . 2 HCl cis
146	16	H	H	CH ₂			mp. 170.0°C . 2 HCl . H ₂ O
147	18	5-OH	H	CH ₂			mp. 152.1°C ethanedioate (1:2)
148	19	H	H	CH ₂			mp. 235.1°C . 2 HCl . NH ₄ Cl




Co. No.	Ex. No.	R ⁷	R ⁸	X	-CH ₂ -A	$\begin{array}{c} \text{N}-\text{R}^1 \\ \diagup \\ \text{C} \\ \diagdown \\ \text{N}-\text{R}^2 \\ \\ \text{R}^3 \end{array}$	physical data
149	19	H	H	CH ₂	$\begin{array}{c} \text{---N---(CH}_2\text{)}_3\text{---N---} \\ \qquad \qquad \\ \text{H} \qquad \qquad \text{H} \end{array}$	$\begin{array}{c} \text{N-H} \\ \diagup \\ \text{---C---} \\ \\ \text{NH-n.C}_3\text{H}_7 \end{array}$	mp. 149.9°C / . 2 HCl
150	19	H	H	CH ₂	$\begin{array}{c} \text{---N---(CH}_2\text{)}_3\text{---N---} \\ \qquad \qquad \\ \text{H} \qquad \qquad \text{H} \end{array}$	$\begin{array}{c} \text{N-H} \\ \diagup \\ \text{---C---} \\ \\ \text{NH-CH(CH}_3\text{)}_2 \\ \\ \text{N-H} \end{array}$	mp. 97.5°C . 2 HCl
151	19	H	H	CH ₂	$\begin{array}{c} \text{---N---(CH}_2\text{)}_3\text{---N---} \\ \qquad \qquad \\ \text{H} \qquad \qquad \text{H} \end{array}$	$\begin{array}{c} \text{N-H} \\ \diagup \\ \text{---C---} \\ \\ \text{N(CH}_3\text{)}_2 \end{array}$	mp. 156.4°C / . 2HCl . 1/2 (CH ₃) ₂ CH-OH
152	19	7-CH ₃	H	CH ₂	$\begin{array}{c} \text{---N---(CH}_2\text{)}_3\text{---N---} \\ \qquad \qquad \\ \text{H} \qquad \qquad \text{H} \end{array}$	$\begin{array}{c} \text{N-H} \\ \diagup \\ \text{---C---} \\ \\ \text{N(CH}_3\text{)}_2 \end{array}$	mp. 224.4°C / . 2 HCl
153	19	7-C ₂ H ₅	H	CH ₂	$\begin{array}{c} \text{---N---(CH}_2\text{)}_3\text{---N---} \\ \qquad \qquad \\ \text{H} \qquad \qquad \text{H} \end{array}$	$\begin{array}{c} \text{N-H} \\ \diagup \\ \text{---C---} \\ \\ \text{N(CH}_3\text{)}_2 \end{array}$	mp. 214.1°C ethanedioate (1:2)
154	19	7-C ₂ H ₅	H	CH ₂	$\begin{array}{c} \text{---N---(CH}_2\text{)}_3\text{---N---} \\ \qquad \qquad \\ \text{H} \qquad \qquad \text{H} \end{array}$	$\begin{array}{c} \text{N-H} \\ \diagup \\ \text{---C---} \\ \\ \text{NH-CH(CH}_3\text{)}_2 \end{array}$	mp. 157.8°C . 2 HCl. 1/2 H ₂ O
155	20	6-F	H	CH ₂	$\begin{array}{c} \text{---N---(CH}_2\text{)}_3\text{---N---} \\ \qquad \qquad \\ \text{H} \qquad \qquad \text{H} \end{array}$		mp. 228.2°C / . HCl

Table 4



Co. No.	Ex. No.	-CH ₂ -A		physical data
156	11			-
157	11			mp. 105.8°C . 2 HCl . 1/2 H ₂ O
158	16			mp. 242.0°C . 2 HCl . 2 H ₂ O
159	16			mp. 229.4°C/ .2 HCl
160	17			liquid/ . 2 HCl . H ₂ O

Table 5



Co. No.	Ex. No.	R ⁷	R ⁸	Alk ¹		physical data
161	10	H	H	-(CH ₂) ₂ -		mp. 188.6°C ethanedioate (1:1)
162	12	6-Br	H	-(CH ₂) ₃ -		mp. 191.7°C ethanedioate (1:1)
163	12	H	H	-CH(CH ₃)-		mp. 183.0°C (2S) . HCl
164	12	H	H	-CH(CH ₃)-		mp. 182.1°C (2R) . HCl
165	16	H	H	-(CH ₂) ₃ -		mp. 170.6°C ethanedioate (1:2)
166	16	H	H	-(CH ₂) ₂ -		mp. 193.5°C ethanedioate (1:2)
167	16	H	H	-CH(CH ₃)-		mp. 110.6°C (2S) . 2 HCl. 1/2 H ₂ O
168	16	H	H	-CH(CH ₃)-		mp. 205.5°C (2R) . 2 HCl

5

C. Pharmacological example

Example 23 : Segments of basilar arteries taken from pigs (anaesthetised with sodium pentobarbital) were mounted for recording of isometric tension in organ baths. The preparations were bathed in Krebs - Henseleit solution. The solution was kept at 37°C

and gassed with a mixture of 95% O₂ - 5% CO₂. The preparations were stretched until a stable basal tension of 2 grams was obtained.

The preparations were made to constrict with serotonin (3×10^{-7} M). The response to the addition of serotonin was measured and subsequently the serotonin was washed away.

5 This procedure was repeated until stable responses were obtained.

Subsequently the test compound was administered to the organ bath and the constriction of the preparation was measured. This constrictive response is expressed as a percentage of the response to serotonin as measured previously.

The ED₅₀-value (molar concentration) is defined as the concentration at which a test

10 compound causes 50% of the constrictive response obtained with serotonin. Said ED₅₀-values are estimated from experiments on three different preparations.

In table 6 the ED₅₀-values of compounds of formula (I) are presented.

15 Table 6

Co. No.	ED ₅₀ (M)
3	$1.46 \cdot 10^{-7}$
5	$5.15 \cdot 10^{-7}$
13	$4.22 \cdot 10^{-8}$
18	$4.90 \cdot 10^{-8}$
46	$1.00 \cdot 10^{-6}$
48	$3.06 \cdot 10^{-7}$
56	$1.87 \cdot 10^{-7}$
57	$5.42 \cdot 10^{-7}$
62	$3.17 \cdot 10^{-8}$
63	$1.21 \cdot 10^{-7}$
64	$8.97 \cdot 10^{-8}$
65	$2.21 \cdot 10^{-7}$
66	$6.56 \cdot 10^{-7}$
67	$1.77 \cdot 10^{-8}$
68	$3.33 \cdot 10^{-8}$
70	$6.37 \cdot 10^{-9}$
72	$2.34 \cdot 10^{-8}$
73	$3.46 \cdot 10^{-9}$
76	$9.19 \cdot 10^{-9}$
78	$3.54 \cdot 10^{-8}$

Co. No.	ED ₅₀ (M)
82	1.76·10 ⁻⁸
84	1.33·10 ⁻⁸
86	4.16·10 ⁻⁸
87	8.87·10 ⁻⁸
88	7.02·10 ⁻⁹
89	7.94·10 ⁻⁸
95	8.17·10 ⁻⁸
97	9.76·10 ⁻⁸
98	3.42·10 ⁻⁸
99	4.22·10 ⁻⁸
106	3.90·10 ⁻⁸
111	1.67·10 ⁻⁸
113	1.63·10 ⁻⁸
114	9.56·10 ⁻⁸
115	4.51·10 ⁻⁸
116	6.82·10 ⁻⁸
129	4.44·10 ⁻⁷
130	3.36·10 ⁻⁸
133	5.27·10 ⁻⁸
136	8.10·10 ⁻⁷
139	1.50·10 ⁻⁷
148	4.95·10 ⁻⁷
149	9.92·10 ⁻⁸
150	4.69·10 ⁻⁸
151	2.71·10 ⁻⁸
152	5.60·10 ⁻⁸
153	2.18·10 ⁻⁸

D. Composition examples

“Active ingredient” (A.I.) as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof.

Example 24 : ORAL DROPS

500 Grams of the A.I. was dissolved in 0.5 l of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there were added 35 l of

polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 grams of sodium saccharin in 2.5 l of purified water and while stirring there were added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing an oral drop solution comprising 10 mg/ml of A.I.. The resulting solution was filled into
5 suitable containers.

Example 25 : ORAL SOLUTION

9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 l of boiling purified water. In 3 l of this solution were dissolved first 10 grams of 2,3-dihydroxybutanedioic acid and thereafter 20 grams of the A.I. The latter
10 solution was combined with the remaining part of the former solution and 12 l of 1,2,3-propanetriol and 3 l of sorbitol 70% solution were added thereto. 40 Grams of sodium saccharin were dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the
15 active ingredient per teaspoonful (5 ml). The resulting solution was filled in suitable containers.

Example 26 : CAPSULES

20 Grams of the A.I., 6 grams sodium lauryl sulfate, 56 grams starch, 56 grams lactose, 0.8 grams colloidal silicon dioxide, and 1.2 grams magnesium stearate were vigorously
20 stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelatin capsules, comprising each 20 mg of the active ingredient.

Example 27 : FILM-COATED TABLETS

Preparation of tablet core

A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed
25 well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 grams microcrystalline cellulose and 15 grams hydrogenated vegetable oil. The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 mg of the active
30 ingredient.

Coating

To a solution of 10 grams methyl cellulose in 75 ml of denaturated ethanol there was added a solution of 5 grams of ethyl cellulose in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 Grams of
35 polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 grams of magnesium

octadecanoate, 5 grams of polyvinylpyrrolidone and 30 ml of concentrated colour suspension and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 28 : INJECTABLE SOLUTION

- 5 1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxybenzoate were dissolved in about 0.5 l of boiling water for injection. After cooling to about 50°C there were added while stirring 4 grams lactic acid, 0.05 grams propylene glycol and 4 grams of the A.I.. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 l, giving a solution comprising 4 mg/ml of A.I.. The solution was
10 sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.

Example 29 : SUPPOSITORIES


- 3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 Grams surfactant (SPAN®) and triglycerides (Witepsol 555 ®) q.s. ad 300 grams were molten together. The latter mixture was mixed
15 well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37-38°C to form 100 suppositories each containing 30 mg/ml of the A.I.

Example 30 : INJECTABLE SOLUTION

- 60 Grams of A.I. and 12 grams of benzylalcohol were mixed well and sesame oil was added q.s. ad 1 l, giving a solution comprising 60 mg/ml of A.I. The solution was
20 sterilized and filled in sterile containers.


Claims




1. A compound having the formula



a pharmaceutically acceptable acid addition salt thereof, or a stereochemically isomeric form thereof, wherein

- 10 X is O, CH₂ or a direct bond;
 R¹ is hydrogen or C₁₋₆alkyl;
 R² is hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl or C₃₋₆alkynyl;
 R³ is hydrogen or C₁₋₆alkyl; or
 R² and R³ taken together form a bivalent radical of formula -(CH₂)_m- wherein m is 4
 15 or 5; or
 R¹ and R² taken together form a bivalent radical of formula -CH=CH- or of formula -(CH₂)_n-, wherein n is 2, 3 or 4; or
 R³ may represent a bond when R¹ and R² taken together form a bivalent radical of
 formula -CH=CH-CH=, -CH=CH-N=, or -CH=N-CH=, wherein one or two
 20 hydrogen atoms can be replaced by halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, amino,
 mono- or di(C₁₋₆alkyl)amino, mono- or di(C₃₋₆cycloalkyl)amino, aminocarbonyl,
 C₁₋₆alkyloxycarbonylamino, C₁₋₆alkylaminocarbonylamino;
 R⁴ is hydrogen or C₁₋₆alkyl;
 Alk¹ is a bivalent C₁₋₃alkanediyl radical;
 25 A is a bivalent radical of formula :






- wherein each R^5 is hydrogen or C_{1-4} alkyl;
 wherein each R^6 is hydrogen or C_{1-4} alkyl;
 Alk^2 is C_{2-15} alkanediyl or C_{5-7} cycloalkanediyl;
 and each p is 0, 1 or 2;
 R^7 and R^8 each independently are hydrogen, halo, C_{1-6} alkyl, C_{3-6} alkenyl,
 C_{3-6} alkynyl, hydroxy, C_{1-6} alkyloxy, cyano, amino C_{1-6} alkyl, carboxyl,
 C_{1-6} alkyloxycarbonyl, nitro, amino, aminocarbonyl, C_{1-6} alkylcarbonylamino,
 or mono- or di(C_{1-6} alkyl)amino;
 provided that [2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]ethyl guanidine is
 excluded.
2. A compound according to claim 1, wherein Alk^1 is CH_2 .
 3. A compound according to claim 1, wherein X is CH_2 and wherein R^7 and R^8 each
 independently are hydrogen, halo, C_{1-6} alkyl, C_{1-6} alkyloxy, hydroxy, cyano, nitro,
 amino C_{1-6} alkyl, amino, C_{1-6} alkylcarbonylamino.
 4. A compound according to claim 2 or 3 wherein A is a bivalent radical of formula (a),
 wherein R^6 is hydrogen.
 5. A compound according to claim 4, wherein the compound is N -[(3,4-dihydro-2H-1-
 benzopyran-2-yl)methyl]- N' -(1,4,5,6-tetrahydro-2-pyrimidinyl)-1,3-propanediamine,
 a stereochemically isomeric form thereof, or a pharmaceutically acceptable acid
 addition salt thereof.
 6. A composition comprising a pharmaceutically acceptable carrier and as an active
 ingredient an effective vasoconstricting amount of a compound of formula (I) as
 claimed in any of claims 1 to 5.

7. A process of preparing a composition as claimed in claim 6 characterized in that a therapeutically effective amount of a compound as defined in any of claims 1 to 5 is intimately mixed with a pharmaceutically acceptable carrier.

8. A compound as claimed in any of claims 1 to 5 for use as a medicine.

9. An intermediate of formula (IX-a)



10 the pharmaceutically acceptable acid addition salts thereof, and the stereochemically isomeric forms thereof, wherein

X is O, CH₂ or a direct bond;

R² is hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl or C₃₋₆alkynyl;

R³ is hydrogen or C₁₋₆alkyl; or





15 R² and R³ may be taken together to form a bivalent radical of formula -(CH₂)_m-, wherein m is 4 or 5;

R⁴ is hydrogen or C₁₋₆alkyl;

Alk¹ is a bivalent C₁₋₃alkanediyl radical;

A is a bivalent radical of formula :

20



25

wherein each R⁵ is hydrogen or C₁₋₄alkyl;

wherein each R⁶ is hydrogen or C₁₋₄alkyl;

Alk² is C₂₋₁₅alkanediyl or C₅₋₇cycloalkanediyl;

and each p is 0, 1 or 2;

R^7 and R^8 each independently are hydrogen, halo, C_{1-6} alkyl, C_{3-6} alkenyl,

C_{3-6} alkynyl, hydroxy, C_{1-6} alkyloxy, cyano, amino, C_{1-6} alkyl, carboxyl,


C_{1-6} alkyloxycarbonyl, nitro, amino, aminocarbonyl, C_{1-6} alkylcarbonylamino, or mono-

5 or di(C_{1-6} alkyl)amino.

10. A process for preparing a compound as claimed in claim 1 characterized by


a) N-alkylating a diamine of formula (II) wherein X, A, R^4 , R^7 and R^8 are as defined in claim 1, with a reagent of formula (III) wherein R^1 , R^2 and R^3 are as defined in claim 1 and wherein W^1 is a reactive leaving group;

10




b) reductively N-alkylating an aminoderivative of formula (VI) wherein A, R^1 , R^2 and R^3 are as defined in claim 1, with an appropriate aldehyde of formula (V) wherein X, R^4 , R^7 and R^8 are as defined in claim 1 and wherein r is 0, 1 or 2;

15




20


c) N-alkylating an amine of formula (VI), with an intermediate of formula (VII), wherein X, Alk^1 , R^4 , R^7 and R^8 are as defined in claim 1 and wherein W^2 is a reactive leaving group;




- 5 d) debenzylating an intermediate of formula (VIII) wherein R^1 , R^2 , R^3 , R^4 , R^6 , R^7 , R^8 , X , Alk^1 and Alk^2 are as defined in claim 1, thus yielding compounds of formula



- 10 e) hydrolyzing an intermediate of formula (IX-a) wherein R^1 , R^2 , R^3 , R^4 , R^6 , R^7 , R^8 , X , Alk^1 and A are as defined in claim 1, thus yielding compounds of formula



- 15 f) hydrogenating a compound of formula (I-c), wherein R^4 , R^7 , R^8 , X , Alk^1 and A are as defined in claim 1, thus yielding compounds of formula (I-d)



- 20 and optionally converting the compounds of formula (I) into each other by a functional group transformation reaction; and, if desired, converting a compound of formula (I) into a therapeutically active non-toxic acid addition salt, or conversely, converting an acid addition salt into a free base form with alkali; and/or preparing stereochemically isomeric forms thereof.

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C07D405/12; C07D405/14; C07D311/58; C07D405/06
A61K31/35**II. FIELDS SEARCHED**Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5

C07D

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸**III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹**

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH vol. 25, no. 9, 1975, AULENDORF DE pages 1404 - 1408 B.BENKERT ET AL. 'BEZIEHUNGEN ZWISCHEN STRUKTUR UND NORADRENALIN-ENTSPICHERNDER WIRKUNG VON GUANIDIN- UND AMIDINDERIVATEN' cited in the application see page 1404 - page 1405; figure III ---	1,2,6
A	US,A,4 405 622 (A.F. KLUGE.) 20 September 1983 see the whole document ---	1,2,6
A	FR,A,1 366 479 (JANSSEN) 1 June 1964 see page 1 - page 4 -----	1,2,6

¹⁰ Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

09 JUNE 1993

Date of Mailing of this International Search Report

17.06.93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

FRANCOIS J.C.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9300435
SA 72158

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

09/06/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4405622	20-09-83	None	

FR-A-1366479		BE-A- 636238	
		FR-M- 2984	
		GB-A- 1010751	
		NL-A- 296841	
		US-A- 3166561	

EPO FORM P0079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

